Actionable Structural Variant Detection Via RNA-NGS and DNA-NGS in Patients With Advanced Non-Small Cell Lung Cancer

Overview

Journal JAMA Netw Open

Publisher American Medical Association

Specialty General Medicine

Date 2024 Nov 4

PMID 39495511

Authors

Dwight Owen

Rotem Ben-Shachar

Josephine Feliciano

Lisa Gai

Kyle A Beauchamp

Zachary Rivers

Adam J Hockenberry

Genelle Harrison

John Guittar

Catarina Catela

Jerod Parsons

Ezra Cohen

Kate Sasser

Halla Nimeiri

Justin Guinney

Jyoti Patel

Daniel Morgensztern

Affiliations

Soon will be listed here.

Abstract

Importance: The National Comprehensive Cancer Network (NCCN) guidelines for non-small cell lung cancer suggest that RNA next-generation sequencing (NGS) may improve the detection of fusions and splicing variants compared with DNA-NGS alone. However, there is limited adoption of RNA-NGS in routine oncology clinical care today.

Objective: To analyze clinical evidence from a diverse cohort of patients with advanced lung adenocarcinoma and compare the detection of NCCN-recommended actionable structural variants (aSVs; fusions and splicing variants) via concurrent DNA and RNA-NGS vs DNA-NGS alone.

Design, Setting, And Participants: This multisite, retrospective cohort study examined patients sequenced between February 2021 and October 2023 within the deidentified, Tempus multimodal database, consisting of linked molecular and clinical data. Participants included patients with advanced lung adenocarcinoma and sufficient tissue sample quantities for both RNA-NGS and DNA-NGS testing.

Exposures: Received results from RNA-NGS and DNA-NGS solid-tissue profiling assays.

Main Outcomes And Measures: Detection rates of NCCN guideline-based structural variants (ALK, ROS1, RET and NTRK1/2/3 fusions, as well as MET exon 14 skipping splicing alterations) found uniquely by RNA-NGS.

Results: In the evaluable cohort of 5570 patients, median (IQR) age was 67.8 (61.3-75.4) years, and 2989 patients (53.7%) were female. The prevalence of actionable structural variants detected by either RNA-NGS or DNA-NGS was 8.8% (n = 491), with 86.7% (n = 426) of these detected by DNA-NGS. Concurrent RNA-NGS and DNA-NGS identified 15.3% more patients harboring aSVs compared with DNA-NGS alone (491 vs 426 patients, respectively), including 14.3% more patients harboring actionable fusions (376 vs 329 patients) and 18.6% more patients harboring MET exon 14 skipping alterations (115 vs 97 patients). There was no significant association between the assay used for aSV detection and aSV-targeted therapeutic adoption or clinical outcome. Emerging structural variants (eSVs) were found to have a combined prevalence to be 0.7%, with only 47.5% of eSVs detected by DNA-NGS.

Conclusions And Relevance: In this cohort study, the detection of structural variants via concurrent RNA-NGS and DNA-NGS was higher across multiple NCCN-guideline recommended biomarkers compared with DNA-NGS alone, suggesting that RNA-NGS should be routinely implemented in the care of patients with advanced NSCLC.

Citing Articles

Comprehensive study of gene fusions in sarcomas.

Chen N, Zhang Q, Sun L, You X, Chen S, Chen D Invest New Drugs. 2024; 43(1):3-17.

PMID: 39680198 DOI: 10.1007/s10637-024-01486-4.

References

Shaw A, Bauer T, de Marinis F, Felip E, Goto Y, Liu G . First-Line Lorlatinib or Crizotinib in Advanced -Positive Lung Cancer. N Engl J Med. 2020; 383(21):2018-2029. DOI: 10.1056/NEJMoa2027187. View

Rosell R, Gonzalez-Cao M, Codony-Servat J, Molina-Vila M, de Las Casas C, Ito M . Acquired BRAF gene fusions in Osimertinib resistant EGFR-mutant non-small cell lung cancer. Transl Cancer Res. 2023; 12(3):456-460. PMC: 10080327. DOI: 10.21037/tcr-22-2888. View

Jennings L, Arcila M, Corless C, Kamel-Reid S, Lubin I, Pfeifer J . Guidelines for Validation of Next-Generation Sequencing-Based Oncology Panels: A Joint Consensus Recommendation of the Association for Molecular Pathology and College of American Pathologists. J Mol Diagn. 2017; 19(3):341-365. PMC: 6941185. DOI: 10.1016/j.jmoldx.2017.01.011. View

Xia P, Zhang L, Li P, Liu E, Li W, Zhang J . Molecular characteristics and clinical outcomes of complex ALK rearrangements identified by next-generation sequencing in non-small cell lung cancers. J Transl Med. 2021; 19(1):308. PMC: 8283930. DOI: 10.1186/s12967-021-02982-4. View

Doebele R, Drilon A, Paz-Ares L, Siena S, Shaw A, Farago A . Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials. Lancet Oncol. 2019; 21(2):271-282. PMC: 7461630. DOI: 10.1016/S1470-2045(19)30691-6. View

Nokin M, Ambrogio C, Nadal E, Santamaria D . Targeting Infrequent Driver Alterations in Non-Small Cell Lung Cancer. Trends Cancer. 2020; 7(5):410-429. DOI: 10.1016/j.trecan.2020.11.005. View

Konduri K, Gallant J, Chae Y, Giles F, Gitlitz B, Gowen K . EGFR Fusions as Novel Therapeutic Targets in Lung Cancer. Cancer Discov. 2016; 6(6):601-11. PMC: 4893907. DOI: 10.1158/2159-8290.CD-16-0075. View

Camidge D, Kim H, Ahn M, Yang J, Han J, Lee J . Brigatinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung Cancer. N Engl J Med. 2018; 379(21):2027-2039. DOI: 10.1056/NEJMoa1810171. View

Li M, Datto M, Duncavage E, Kulkarni S, Lindeman N, Roy S . Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer: A Joint Consensus Recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists. J Mol Diagn. 2016; 19(1):4-23. PMC: 5707196. DOI: 10.1016/j.jmoldx.2016.10.002. View

10.

Lindeman N, Cagle P, Aisner D, Arcila M, Beasley M, Bernicker E . Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer,.... J Thorac Oncol. 2018; 13(3):323-358. DOI: 10.1016/j.jtho.2017.12.001. View

11.

Subbiah V, Wolf J, Konda B, Kang H, Spira A, Weiss J . Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open-label, basket trial. Lancet Oncol. 2022; 23(10):1261-1273. PMC: 11702314. DOI: 10.1016/S1470-2045(22)00541-1. View

12.

Shaw A, Riely G, Bang Y, Kim D, Camidge D, Solomon B . Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001. Ann Oncol. 2019; 30(7):1121-1126. PMC: 6637370. DOI: 10.1093/annonc/mdz131. View

13.

Zhang N, Liu Y, Ma L, Wang L, Hao X, Yuan Z . The molecular detection and clinical significance of ALK rearrangement in selected advanced non-small cell lung cancer: ALK expression provides insights into ALK targeted therapy. PLoS One. 2014; 9(1):e84501. PMC: 3880316. DOI: 10.1371/journal.pone.0084501. View

14.

Socinski M, Pennell N, Davies K . Exon 14 Skipping Mutations in Non-Small-Cell Lung Cancer: An Overview of Biology, Clinical Outcomes, and Testing Considerations. JCO Precis Oncol. 2021; 5. PMC: 8140815. DOI: 10.1200/PO.20.00516. View

15.

Wong D, Yip S, Sorensen P . Methods for Identifying Patients with Tropomyosin Receptor Kinase (TRK) Fusion Cancer. Pathol Oncol Res. 2019; 26(3):1385-1399. PMC: 7297824. DOI: 10.1007/s12253-019-00685-2. View

16.

Liu Z, Roberts R, Mercer T, Xu J, Sedlazeck F, Tong W . Towards accurate and reliable resolution of structural variants for clinical diagnosis. Genome Biol. 2022; 23(1):68. PMC: 8892125. DOI: 10.1186/s13059-022-02636-8. View

17.

Davies K, Lomboy A, Lawrence C, Yourshaw M, Bocsi G, Camidge D . DNA-Based versus RNA-Based Detection of MET Exon 14 Skipping Events in Lung Cancer. J Thorac Oncol. 2019; 14(4):737-741. DOI: 10.1016/j.jtho.2018.12.020. View

18.

Yang S, Aypar U, Rosen E, Mata D, Benayed R, Mullaney K . A Performance Comparison of Commonly Used Assays to Detect RET Fusions. Clin Cancer Res. 2020; 27(5):1316-1328. PMC: 8285056. DOI: 10.1158/1078-0432.CCR-20-3208. View

19.

Paik P, Felip E, Veillon R, Sakai H, Cortot A, Garassino M . Tepotinib in Non-Small-Cell Lung Cancer with Exon 14 Skipping Mutations. N Engl J Med. 2020; 383(10):931-943. PMC: 8422679. DOI: 10.1056/NEJMoa2004407. View

20.

Cohen D, Hondelink L, Solleveld-Westerink N, Uljee S, Ruano D, Cleton-Jansen A . Optimizing Mutation and Fusion Detection in NSCLC by Sequential DNA and RNA Sequencing. J Thorac Oncol. 2020; 15(6):1000-1014. DOI: 10.1016/j.jtho.2020.01.019. View